[{"id":"d1f2bba3-a066-4ab2-ade4-ee5dabc41dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00781911","created_at":"2021-01-18T02:57:16.581Z","updated_at":"2024-07-02T16:36:55.434Z","phase":"Phase 2","brief_title":"A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer","source_id_and_acronym":"NCT00781911","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cixutumumab (IMC A12) • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2019-09-20"},{"id":"dcf070b8-c1c9-42c7-86fb-590929bf423e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299089","created_at":"2021-01-18T10:50:48.870Z","updated_at":"2025-02-25T15:42:05.057Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","source_id_and_acronym":"NCT02299089","lead_sponsor":"Camurus AB","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oclaiz (octreotide subcutaneous depot) • octreotide acetate • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-12-15"}]